Baidu
map

Science重大成果:神奇的再生药丸

2015-06-12 佚名 生物通

服下一片药丸,新组织就会突然长出来替换受损的组织,这一想法听起来有点像是科幻小说。来自凯斯西储大学和德克萨斯大学西南医学中心的研究人员本周宣布,他们在将这一曾经看似不可能的想法变为鲜活现实的道路上迈出了重要的步伐。在发表于6月12日《科学》(Science)杂志上的一项新研究中,他们描述了一种新药如何修复了动物模型中的结肠、肝脏和骨髓损伤——甚至挽救了骨髓移植模型中本来会死掉的小鼠的生命。凯斯

服下一片药丸,新组织就会突然长出来替换受损的组织,这一想法听起来有点像是科幻小说。

来自凯斯西储大学和德克萨斯大学西南医学中心的研究人员本周宣布,他们在将这一曾经看似不可能的想法变为鲜活现实的道路上迈出了重要的步伐。在发表于6月12日《科学》(Science)杂志上的一项新研究中,他们描述了一种新药如何修复了动物模型中的结肠、肝脏和骨髓损伤——甚至挽救了骨髓移植模型中本来会死掉的小鼠的生命。

凯斯西储大学医学院癌症遗传学教授、大学医院凯斯医学中心Seidman癌症中心医学肿瘤学家Sanford Markowitz博士说:“我们感到非常的兴奋。我们开发出了一种作用像维生素的药物,它能够刺激组织干细胞更快速地修复组织。这一药物治愈了多个器官的损伤,向我们表明了它可以应用于治疗许多的疾病。”

合作从事这项研究工作的机构希望进一步开发这一药物“SW033291”使之适用于人类患者。鉴于取得初步成功的领域,他们将首先把焦点放在接受骨髓移植、罹患溃疡性结肠炎,以及接受肝脏手术的个体身上。其目的完全相同:都是要大幅度提高这些个体更快速及成功康复的机会。

这一药物的潜能与身体产生的一种叫做前列腺素E2(PGE2)有关联。众所周知,PGE2支持了许多类型组织干细胞的增殖。Markowitz和肯塔基大学教授Hsin-Hsiung Tai早些时候证实了,存在于所有人类身上的一种基因产物15-羟基前列腺素脱氢酶(15-PGDH)可以降解及减少体内的PGE2量。

Markowitz和凯斯西储大学的前同事James K.V. Willson博士猜测,抑制15-PGDH会提高组织中的PGE2,由此将会促进及加速组织愈合。当用缺失15-PGDH的遗传工程小鼠进行实验时证实了他们的想法是对的,两人于是开始寻找一种可以短期失活15-PGDH的方法。

初期的研究工作是在试管中完成。论文的第一作者、凯斯西储大学助理研究员Yongyou Zhang博士开发了一种测试,在这一测试中当15-PGDH水平发生改变时细胞会发光。Yongyou Zhang随后去到了德克萨斯大学西南医学中心的Harold C. Simmons综合癌症中心,与研究员Bruce Posner博士和Joseph Ready博士合作,筛查了该中心包含230,000种不同化学药物的药品库。最终他们发现了一种可以失活15-PGDH的化学药物。

Markowitz说:“这一化学药物SW033291以一种令人难以置信的强大方式发挥作用。当以100亿分之一的比例添加到一种反应混合物中时它都可以失活15-PGDH,这意味着它有希望像药物那样起作用。”

一系列的实验表明,在试管中,细胞内,以及最为重要的是注射到动物模型体内时,SW033291都可以失活15-PGDH。Markowitz与凯斯综合癌症中心主任Stanton L. Gerson合作获得了第三个研究结果。

凯斯西储大学助理研究员Amar Desai博士与Markowitz及Gerson实验室合作,确定了SW033291对受到致死剂量辐射,随后接受骨髓移植手术的小鼠的影响。没有SW033291,这些动物会死亡。有了它,小鼠恢复了健康。
更为详细的研究表明,给予SW033291的小鼠相比于那些没有给予SW033291而接受移植的小鼠要快6天恢复正常血细胞计数。此外,SW033291处理小鼠中性粒细胞、血小板和红细胞均以更快地速度恢复。中性粒细胞负责对抗感染,血小板能够防止出血,红细胞将氧气输送到全身。

此外,Desai的研究工作表明,当SW033291提高骨髓中的PGE2时,机体也开始生成骨髓干细胞生存需要的其他物质。最终他们还证实,在显现这些利益的同时没有任何不良副作用,即便SW033291的剂量已远远高于抑制15-PGDH所需的剂量。
当研究人员用SW033291处理罹患其他疾病的小鼠时,这一药物再次加速了组织复原。例如,研究人员与凯斯西储大学教授、胃肠病学和肝病科主任Fabio Cominelli合作,研究了溃疡性结肠炎的小鼠模型。SW033291治愈了动物结肠中几乎所有的溃疡,并阻止了肠炎症状。在三分之二的肝脏被手术切除的小鼠中,SW033291以比正常情况下未接受药物处理时快近2倍的速度加速了新肝脏再生。

由于骨髓、结肠和肝脏是明显不同的组织,研究人员相信SW033291加速组织再生的这一信号通路有可能可以同样地发挥作用,来治疗机体许多其他组织疾病。但下一阶段的研究还是会把焦点放在SW033291已显示出前景,有望明显改善的3种疾病上。

例如在骨髓移植中,SW033291加速组织生长的效应可为机体提供对抗两种最常见、有时致命的并发症——感染和出血必需的细胞。对于那些忍受着结肠炎破坏性影响的人而言,加速组织生长可以更快速地愈合结肠溃疡,转而使得患者能够服用较低剂量的其他药物来治疗结炎——其中一些药物有着严重的副作用。最后,组织生长有望提高肝癌患者的生存率;在当前的某些情况下,医生无法进行手术就是因为切除大部分的肝脏会给患者带来严重的风险。有了可以加速肝脏再生的一种药物,则可以让手术成为一种可行的方案。

研究人员下一阶段将在更大型的动物中完成证实SW033291相关化合物安全性的研究,这是获得美国食品药品管理局批准开展人类实验要求完成的部分工作。如果在这些临床实验中药物证实是安全和有效的,它们将提供给医生使用。研究人员希望能够在三年内与制药公司合作启动人类试验。


原始出处:

Yongyou Zhang,et,al.Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.Science 12 June 2015:Vol. 348 no. 6240 DOI: 10.1126/science.aaa2340 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-29 owlhealth

    挺好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-14 Gujun

    人工成瘤

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-14 jichang
  6. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 sumer

    应该会有潜在的致癌性

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    了不起

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    赞一个

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 zyl092078

    相当了不起的结果。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=29923, encodeId=69f329923c5, content=挺好, beContent=null, objectType=article, channel=null, level=null, likeNumber=155, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3b2c1627329, createdName=owlhealth, createdTime=Mon Jun 29 18:51:00 CST 2015, time=2015-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=29387, encodeId=06072938e0e, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:42:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27723, encodeId=083c2e7237c, content=高, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acd01628312, createdName=1dd82894m82(暂无匿称), createdTime=Mon Jun 15 23:36:00 CST 2015, time=2015-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27607, encodeId=cc9b2e60724, content=人工成瘤, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dee51627209, createdName=Gujun, createdTime=Sun Jun 14 20:32:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375055, encodeId=7e6413e5055de, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun Jun 14 07:11:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27538, encodeId=3f272e53881, content=应该会有潜在的致癌性, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c061611816, createdName=sumer, createdTime=Sat Jun 13 09:39:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27429, encodeId=a3202e42973, content=了不起, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27430, encodeId=31832e43033, content=赞一个, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 01:30:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27388, encodeId=4ce12e388bc, content=相当了不起的结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=126, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=611974228, createdName=zyl092078, createdTime=Fri Jun 12 22:43:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27337, encodeId=72852e337f4, content=really?, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Fri Jun 12 19:02:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 qinweihan19

    really?

    0

相关资讯

ACS AMI:新型骨修复生物材料

记者从东华大学获悉,该校生物科学与技术研究所张彦中教授课题组利用电纺丝技术结合新型的形状记忆聚合物,研制出一种具有形状记忆效应的组织工程仿生支架。相关研究成果日前发表于《美国化学会—应用材料与界面》。美国化学会周刊《化学化工新闻》对此也进行了专门报道。 骨折是常见的骨科伤病,约有10%的伤者会因骨折愈合钢钉取出后在骨头上留下骨钉孔而有再骨折的危险。如何降低再骨折发生率,对骨的力学缺陷进行“补强”

液态金属导线修复破损神经

         为了“攻克”严重的神经损伤问题,全球的研究者们进行了大量的工作,其中既有让神经传导信号绕过受损神经部位,又有使用干细胞进行神经再生等的方法。但清华大学的研究者在2014年4月发表于arXiv上的一项研究则采用了不同的方法,他们采用一种在体温时呈液态的GalnSn合金(67%的镓、20.

J Oral Rehabil:口腔功能的恢复——可摘义齿仍是一个选择

J Oral Rehabil:口腔功能的恢复——可摘义齿仍是一个选择口腔功能,包括咀嚼,吞咽,美观,感觉以及语言。很多原因,如牙齿丧失,肌肉功能障碍,肿瘤,颞下颌关节紊乱病等,均可影响口腔功能。患者还会遭遇越来越多的社会和心理方面的困难。各种修复体的应用为恢复口腔功能提供了一种方法,其中可摘义齿作为修复缺失牙的手段已有悠久的历史。义齿修复恢复口腔功能时,常需恢复患者的咀嚼,美观

ASA2013:血管外科修复主动脉瘤效果更理想

全美医院数据库的全面分析显示,就死亡率、住院时间和住院总费用等患者的主要结局而言,与心脏科医生或介入放射科医生相比,由血管外科医生实施腹主动脉瘤血管内修复术效果更佳。“显然这是令人震惊的发现,” 加州大学圣迭戈分校外科主任Mark A. Talamini教授在美国外科学会(ASA)2013年会上报告称,“我们认为应该考虑制定相关的卫生政策以支持动脉瘤修复患者的选择性转诊,或者考虑以更加有效的方式来

Nat Cell Biol:促进乳腺癌细胞对放射疗法产生耐受的特殊蛋白ZEB1

近日,来自美国德州大学MD安德森癌症中心的研究人员通过研究发现,一种名为ZEB1(锌指E盒结合同源框蛋白)的蛋白质可以促进乳腺癌对放射疗法产生耐受性,研究者Li Ma博士表示,蛋白质ZEB1实际上可以帮助乳腺肿瘤细胞修复因辐射疗法带来的DNA损伤,而实现这一修复的机制或许是通过DNA损伤反应路径,相关研究刊登于国际杂志Nature Cell Biology上。 放射疗法可以通过诱导DNA破

Structure:阻止癌细胞DNA修复治疗癌症

来自加拿大阿尔伯塔大学的研究人员公布了一项基础科学研究的最新成果,他们发现DNA自我修复的奥秘,由于DNA损伤过于严重的时候就会引发癌症,因此这一研究成果将有助于癌症治疗。 这一研究成果公布在Cell出版社旗下的Structure杂志上,由阿尔伯塔大学研究员Mark Glover和他的同事们共同完成。【原文下载】 多年来,科学家们一直认为DNA修复过程中的两个关键蛋白所采用的

Baidu
map
Baidu
map
Baidu
map